News Sentiment

SGMT sentiment intelligence

Sagimet Biosciences Inc. Series A Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 67 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 7.37 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 60

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend active

-3.2% over one week, +13.7% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

Sagimet Biosciences (SGMT) Attracts Attention After Russel Indexes Inclusion

Market Reaction

Balanced read

64/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction -3.2% Price reacting lower
Trend fit Trend active 13.7% over four weeks
Fair value 22.7% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 52
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 60
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
Stock Titan 12
TradingView 8
GlobeNewswire 7
The Globe and Mail 4
simplywall.st 3
TipRanks 2
Seeking Alpha 2

Event Lens

What the news is about

Classified themes
Market update 41
Earnings 20
Analyst action 4
Balance sheet 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 67
TradingView Direct company coverage

Price to earnings forward of Sagimet Biosciences Inc. Class A – SWB:0O2

This article provides access to the "Price to earnings forward" financial metric for Sagimet Biosciences Inc. Class A (SWB:0O2) on the Stuttgart Stock Exchange, as tracked by TradingView. It highlights that the market was closed with no trades at the time of the data. The content

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 09:10
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Sagimet Biosciences Inc. Class A – LS:A3CPAM

This article provides financial information for Sagimet Biosciences Inc. Class A (LS:A3CPAM), specifically focusing on its price-to-earnings forward metric. The data is sourced from ICE Data Services and FactSet, indicating market closure and current lack of trades.

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 21:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Sagimet Biosciences Inc. Class A – LS:A3CPAM

This article provides financial information for Sagimet Biosciences Inc. Class A (LS:A3CPAM), specifically focusing on its enterprise value to EBIT forward metric. The content highlights that the market for this stock is currently closed with no trades. It also details the variou

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 00:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Sagimet Biosciences Inc. Class A – LS:A3CPAM

This page provides financial information for Sagimet Biosciences Inc. Class A (LS:A3CPAM), specifically focusing on its forward price to sales ratio. The content also briefly touches upon market data sources and copyright information.

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 10:09
Source
TradingView
TradingView Direct company coverage

0O2 Forecast — Price Target — Prediction for 2027

This article provides a price target and forecast for Sagimet Biosciences Inc. Class A (0O2) based on analyst opinions. It details maximum and minimum price estimates, past price performance, upcoming earnings reports, and financial metrics like revenue and net income. The articl

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 16:40
Source
TradingView
TradingView Direct company coverage

Sagimet Biosciences Inc. Class A Actuals & Estimates (NASDAQ:SGMT)

This article provides an overview of Sagimet Biosciences Inc. (NASDAQ:SGMT) stock, including its current price, historical performance, analyst forecasts, and financial details. It covers key metrics like market capitalization, volatility, earnings reports, and revenue, alongside

Tone
Positive 62/100
Event
Earnings
Published
26 Jun 2026 03:40
Source
TradingView
Stock Titan Direct company coverage

Sagimet Biosciences (SGMT) director resigns as shareholders elect Board, ratify KPMG

Sagimet Biosciences Inc. reported that director Tim Walbert resigned from its Board effective June 12, 2026, due to other commitments, with no disagreements cited. During their 2026 Annual Meeting, shareholders elected four Class III directors—Jennifer Jarrett, Anne Phillips, M.D

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 20:08
Source
Stock Titan
TipRanks Direct company coverage

Sagimet Biosciences Grants New Performance-Based Executive Equity Awards

Sagimet Biosciences (SGMT) recently granted significant performance-based executive equity awards to its CEO, CFO, and Chief Legal and Administrative Officer. These awards, issued on May 28, 2026, include stock options vesting over 48 months and performance-based restricted stock

Tone
Positive 66/100
Event
Market update
Published
04 Jun 2026 19:10
Source
TipRanks
Stock Titan Direct company coverage

Sagimet Biosciences (SGMT) CLO awarded 100,000 stock options at $7.27

Sagimet Biosciences Inc. reported that its Chief Legal & Admin. Officer, Elizabeth Rozek, was granted 100,000 stock options. These options have an exercise price of $7.27 per share and an expiration date of May 27, 2036. The shares associated with these options will vest in 48 eq

Tone
Neutral 50/100
Event
Market update
Published
02 Jun 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

Sagimet Biosciences (SGMT) CMO receives 35,000 stock options at $7.27 strike

Sagimet Biosciences (SGMT) Chief Medical Officer, Andreas Grauer, was granted 35,000 stock options with an exercise price of $7.27 per share. These options will vest in 48 equal monthly installments starting May 28, 2026, contingent upon his continued service. Grauer now directly

Tone
Neutral 50/100
Event
Market update
Published
02 Jun 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

Sagimet Biosciences (SGMT) grants CEO options on 300,000 shares

Sagimet Biosciences Inc. (SGMT) reported that its President & CEO, David Happel, was granted stock options for 300,000 shares of Series A common stock. These options have an exercise price of $7.27 per share and will vest in 48 equal monthly installments starting May 28, 2026, co

Tone
Neutral 50/100
Event
Market update
Published
02 Jun 2026 19:40
Source
Stock Titan
The Globe and Mail Direct company coverage

Analysts Conflicted on These Healthcare Names: MannKind (MNKD), Biohaven Ltd. (BHVN) and Precision BioSciences (DTIL)

This article summarizes analyst ratings for three healthcare companies: MannKind (MNKD), Biohaven Ltd. (BHVN), and Precision BioSciences (DTIL). MannKind received a "Strong Buy" consensus with Wedbush maintaining a "Buy" rating. Biohaven Ltd. has a "Moderate Buy" consensus, with

Tone
Neutral 50/100
Event
Analyst action
Published
30 May 2026 04:39
Source
The Globe and Mail
The Globe and Mail Direct company coverage

Analysts Offer Insights on Healthcare Companies: Armata Pharmaceuticals (ARMP), Palvella Therapeutics (PVLA) and MBX Biosciences, Inc. (MBX)

Three analysts have provided bullish insights on healthcare companies Armata Pharmaceuticals (ARMP), Palvella Therapeutics (PVLA), and MBX Biosciences, Inc. (MBX). Armata Pharmaceuticals received a Buy rating with a $20.00 price target, Palvella Therapeutics also received a Buy r

Tone
Neutral 50/100
Event
Analyst action
Published
20 May 2026 13:09
Source
The Globe and Mail
Stock Titan Direct company coverage

Sagimet Biosciences (NASDAQ: SGMT) cuts R&D spend and raises $175M equity

Sagimet Biosciences reported a reduced net loss of $10.7 million for Q1 2026, down from $18.2 million in Q1 2025, primarily due to a 54% decrease in R&D expenses as MASH work wound down and focus shifted to acne programs. The company bolstered its financial position by raising $1

Tone
Positive 65/100
Event
Market update
Published
16 May 2026 00:39
Source
Stock Titan